Development of Gene Therapy for Age-Related Macular-Degeneration (AMD)

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: closed (31 December 2016) | Viewed by 160

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedicine, Faculty of Health, Aarhus University, Wilhelm Meyers Allé 4, 8000 Aarhus C, Denmark
Interests: gene therapy; eye gene therapy; AMD; viral vectors (AAV and LV); gene silencing; gene editing; anti-angiogenic RNAi; anti-angiogenic proteins

Special Issue Information

Dear Colleagues,

The main focus of this Special Issue, entitled “Development of Gene Therapy for Age-Related Macular-Degeneration (AMD)”, will be on regeneration of retinal function and the different aspects of anti-angiogenic eye gene therapy, gene therapy of dry AMD, and gene editing-based therapy. Over the last decade, significant progress exploiting gene supplementation and silencing approaches based on viral vector delivery has been made in the field of ocular gene therapy. This success underlines ocular gene therapy as a significant propellant in moving genetically based therapy from bench to bedside. In this Special Issue, papers can be centered on viral and non-viral platforms for RNAi and protein-based anti-angiogenic gene therapy for wet AMD, their usability for therapy of dry AMD, their applicability for combination therapy, ex vivo therapy and cell-phenotype rescue, and their adaptations for sustained and safe therapy. Both preclinical and clinical findings in form of either research papers or reviews will be considered.

Dr. Thomas J. Corydon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Eye gene therapy
  • AMD
  • Retina
  • Viral vectors (integrating and non-integrating)
  • Non-viral vectors
  • Gene silencing
  • Gene editing
  • RNAi
  • Anti-angiogenic therapy

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop